Skip to main content
Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.930
+0.110 (6.04%)
At close: Mar 9, 2026, 4:00 PM EDT
1.890
-0.040 (-2.07%)
After-hours: Mar 9, 2026, 5:41 PM EDT

Coherus Oncology Revenue

Coherus Oncology had revenue of $11.57M in the quarter ending September 30, 2025, with 91.19% growth. This brings the company's revenue in the last twelve months to $277.73M, up 152.07% year-over-year. In the year 2024, Coherus Oncology had annual revenue of $266.96M with 3.78% growth.

Revenue (ttm)
$277.73M
Revenue Growth
+152.07%
P/S Ratio
1.04
Revenue / Employee
$1,757,772
Employees
158
Market Cap
288.48M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024266.96M9.72M3.78%
Dec 31, 2023257.24M46.20M21.89%
Dec 31, 2022211.04M-115.51M-35.37%
Dec 31, 2021326.55M-149.27M-31.37%
Dec 31, 2020475.82M119.75M33.63%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Cellectis 82.55M
OmniAb 18.67M
Ovid Therapeutics 6.61M
AC Immune 5.48M
Silence Therapeutics 559.00K
Abeona Therapeutics 400.00K
Revenue Rankings

CHRS News

More News